National Health (Pharmaceutical Benefits Early Supply) Amendment Instrument 2014 (No. 2) specification under subsection 84AAA(2) (No. PB 34 of 2014) (Cth)

PB 34 of 2014

National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 2) – specification under subsection 84AAA(2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated    9 April 2014

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment determination – Pharmaceutical Benefits – Early Supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 2) – specification under subsection 84AAA(2).

(2)      This Instrument may also be cited as PB 34 of 2014.

2          Commencement

This Instrument commences on 1 May 2014.

3          Amendment of PB 30 of 2009

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).

Schedule 1        Amendments

[1]    Schedule 1, column headings

(a)omit:        Form (strength, type, size, etc.)            substitute        Form

(b)omit:        Maximum repeats              substitute        Maximum number of repeats

[2]    Schedule 1, entry for Amlodipine

omit:

Tablet 5 mg (as maleate)	Oral	30	5
Tablet 10 mg (as maleate)	Oral	30	5

[3]    Schedule 1, entry for Dabigatran

omit from the column headed “Listed drug”:         Dabigatran            substitute:     Dabigatran etexilate

[4]    Schedule 1, entry for Nilotinib in the form Capsule 200 mg (as hydrochloride monohydrate)

omit from the column headed “Listed drug”:         Nilotinib               [name of listed drug exists]

[5]    Schedule 1, omit entry for Pergolide

[6]    Schedule 1, entry for Rivaroxaban

omit from the column headed “Form”:                    Tablet, 15mg           substitute:      Tablet 15 mg

[7]    Schedule 1, after entry for Salcatonin in the form Injection 100 I.U. in 1 mL ampoule

insert:

Sapropterin Tablet (soluble) containing sapropterin hydrochloride 100 mg Oral 180 5

[8]    Schedule 1, entry for Verapamil

omit:

Tablet containing verapamil hydrochloride 120 mg Oral 100 5